ANI Pharmaceuticals (ANIP)
(Delayed Data from NSDQ)
$65.50 USD
+0.14 (0.21%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $65.53 +0.03 (0.05%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth D Momentum B VGM
Income Statements
Fiscal Year end for ANI Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 487 | 316 | 216 | 208 | 207 |
Cost Of Goods | 182 | 139 | 101 | 87 | 63 |
Gross Profit | 305 | 178 | 116 | 121 | 143 |
Selling & Adminstrative & Depr. & Amort Expenses | 258 | 213 | 155 | 137 | 127 |
Income After Depreciation & Amortization | 47 | -35 | -40 | -16 | 16 |
Non-Operating Income | 0 | 1 | -4 | 0 | 0 |
Interest Expense | 27 | 28 | 12 | 9 | 13 |
Pretax Income | 20 | -63 | -56 | -26 | 3 |
Income Taxes | 1 | -15 | -13 | -3 | -3 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 19 | -48 | -43 | -23 | 6 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 19 | -48 | -43 | -23 | 6 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 107 | 24 | 7 | 29 | 61 |
Depreciation & Amortization (Cash Flow) | 60 | 60 | 47 | 45 | 45 |
Income After Depreciation & Amortization | 47 | -35 | -40 | -16 | 16 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 18.19 | 16.26 | 12.60 | 11.96 | 12.04 |
Diluted EPS Before Non-Recurring Items | 3.85 | 0.68 | 2.58 | 2.87 | 4.46 |
Diluted Net EPS (GAAP) | 0.85 | -3.05 | -3.40 | -1.88 | 0.50 |
Fiscal Year end for ANI Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 131.65 | 131.83 | 116.55 | 106.79 |
Cost Of Goods | NA | 53.42 | 48.10 | 42.28 | 37.71 |
Gross Profit | NA | 78.23 | 83.73 | 74.26 | 69.08 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 71.51 | 65.78 | 61.86 | 59.18 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 6.72 | 17.95 | 12.40 | 9.90 |
Non-Operating Income | NA | -0.03 | -0.04 | -0.05 | -0.03 |
Interest Expense | NA | 5.75 | 6.40 | 7.10 | 7.70 |
Pretax Income | NA | 0.95 | 11.51 | 5.25 | 2.17 |
Income Taxes | NA | -0.21 | 1.57 | -1.00 | 0.73 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 1.16 | 9.94 | 6.25 | 1.44 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 1.16 | 9.94 | 6.25 | 1.44 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 19.22 | 19.13 | 17.86 | 16.53 |
Diluted EPS Before Non-Recurring Items | NA | 0.78 | 1.05 | 1.06 | 0.97 |
Diluted Net EPS (GAAP) | NA | 0.05 | 0.45 | 0.29 | 0.06 |